Teva, AbbVie Tell 3rd Circ. New Precedent Won't Help Buyers

By Craig Clough (February 24, 2023, 10:53 PM EST) -- AbbVie and Teva Pharmaceuticals pushed back Thursday after buyers of the cholesterol drug Niaspan asked the Third Circuit to consider one of its 2022 opinions before deciding whether to deny them class certification in a suit accusing the pharma companies of a pay-for-delay deal, saying the opinion actually supports denying certification....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!